Media headlines about Cancer Genetics (NASDAQ:CGIX) have been trending somewhat positive on Wednesday, according to Accern. The research firm scores the sentiment of media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Cancer Genetics earned a coverage optimism score of 0.23 on Accern’s scale. Accern also assigned news coverage about the medical research company an impact score of 44.8807023103223 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Here are some of the media stories that may have effected Accern Sentiment Analysis’s analysis:

Cancer Genetics (NASDAQ CGIX) traded up $0.07 during midday trading on Wednesday, hitting $2.03. 106,179 shares of the company traded hands, compared to its average volume of 256,996. The company has a quick ratio of 2.01, a current ratio of 2.01 and a debt-to-equity ratio of 0.18. Cancer Genetics has a fifty-two week low of $1.30 and a fifty-two week high of $5.30.

A number of research analysts recently commented on the stock. HC Wainwright reaffirmed a “buy” rating and set a $6.00 price objective on shares of Cancer Genetics in a research report on Thursday, September 21st. Zacks Investment Research raised shares of Cancer Genetics from a “sell” rating to a “hold” rating in a research report on Wednesday, November 29th. ValuEngine downgraded shares of Cancer Genetics from a “sell” rating to a “strong sell” rating in a research report on Friday, December 1st. Finally, Maxim Group initiated coverage on shares of Cancer Genetics in a research report on Thursday, December 7th. They issued a “buy” rating and a $6.00 target price for the company. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $5.56.

In other news, Director John Pappajohn acquired 150,000 shares of the firm’s stock in a transaction that occurred on Friday, December 8th. The stock was acquired at an average cost of $1.86 per share, with a total value of $279,000.00. Following the acquisition, the director now owns 2,781,204 shares in the company, valued at $5,173,039.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 21.30% of the stock is currently owned by corporate insiders.

ILLEGAL ACTIVITY WARNING: This story was first published by Watch List News and is the property of of Watch List News. If you are accessing this story on another website, it was copied illegally and republished in violation of US & international copyright laws. The original version of this story can be read at

About Cancer Genetics

Cancer Genetics, Inc is a United States-based company, which is engaged in the field of personalized medicine. The Company offers diagnostic products and services that enable precision medicine in the field of oncology through molecular markers and diagnostics. The Company offers a range of laboratory services that provide genomic and biomarker information.

Insider Buying and Selling by Quarter for Cancer Genetics (NASDAQ:CGIX)

Receive News & Ratings for Cancer Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cancer Genetics and related companies with's FREE daily email newsletter.